This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

This study has been completed.
Information provided by:
Arena Pharmaceuticals Identifier:
First received: January 22, 2009
Last updated: July 27, 2009
Last verified: July 2009
The purpose of this study is to evaluate and establish whether lorcaserin dose adjustment is required in patients with mild or moderate hepatic impairment.

Condition Intervention Phase
Hepatic Impairment Drug: Lorcaserin Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: An Open Label, Single Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

Resource links provided by NLM:

Further study details as provided by Arena Pharmaceuticals:

Primary Outcome Measures:
  • The primary objective of this study is to evaluate the pharmacokinetic properties of lorcaserin in subjects with mild or moderate hepatic impairment compared to subjects with normal hepatic function.

Secondary Outcome Measures:
  • To evaluate the safety and tolerability of lorcaserin

Estimated Enrollment: 24
Study Start Date: August 2008
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lorcaserin 10mg Drug: Lorcaserin


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Males or females aged between 18 and 75 years (inclusive)
  2. Able to give signed informed consent
  3. Hepatic function will fall into one of the following categories:

    • One-third of patients will have normal hepatic function (defined as having all of the following parameters within the normal range of the clinical laboratory used for this trial: AST, ALT, alkaline phosphatase, total bilirubin)
    • One-third of patients will have mild impairment (Child-Pugh score 5-6)
    • One-third of patients will have moderate impairment (Child-Pugh score 7-9)
  4. All subjects will have a BMI of 27-45 kg/m2, inclusive.
  5. Eligible male and female patients must agree not to participate in a conception process
  6. Considered to be in stable health in the opinion of the Investigator.

Exclusion Criteria:

  1. Prior participation in any study of lorcaserin.
  2. Clinically significant new illness in the 1 month before screening
  3. Not suitable to participate in the study in the opinion of the Investigator including an existing physical or mental condition that prevents compliance with the protocol
  4. History of any of the following cardiovascular conditions:

    • Myocardial infarction (diagnosed by cardiac enzyme[s] and/or diagnostic ECG), CVA, TIA or RIND within 6 months of screening
    • Cardiac arrhythmia requiring initiation of new medical or surgical treatment within 6 months of screening (stable medical therapy for > 6 months, pacemakers and/or defibrillators implanted > 6 months prior to screening are acceptable)
    • Unstable angina
  5. Surgically implanted portacaval shunts are excluded with the following exception: transjugular intrahepatic portosystemic shunts (TIPS) will be allowed if placed no less than 3 months prior to dosing
  6. Malignancy within 2 years of the screening visit (except basal cell or squamous cell carcinoma with clean surgical margins)
  7. Initiation of a new prescription medication within 1 month prior to screening.
  8. Recent history (within 3 months prior to the screening visit) of alcohol or drug/solvent abuse or a positive screen for drugs of abuse at screening.
  9. Use of SSRI's, SNRI's, and other medications must meet the required washout periods.
  10. Participated in any clinical study with an investigational drug, biologic, or device within 1 month prior to dosing
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00828932

United States, Florida
Orlando Clinical Research Center
Orlando, Florida, United States, 32809
Sponsors and Collaborators
Arena Pharmaceuticals
OverallOfficial: Christen Anderson, MD, PhD Arena Pharmaceuticals
  More Information

Responsible Party: Christen Anderson, MD, PhD, Arena Pharmaceuticals, INc. Identifier: NCT00828932     History of Changes
Other Study ID Numbers: APD356-017
Study First Received: January 22, 2009
Last Updated: July 27, 2009

Additional relevant MeSH terms:
Liver Diseases
Digestive System Diseases processed this record on August 22, 2017